GPhA comes out tentatively in favor of risk-based FDA inspections; Lannett gets plant with Kremers buy;

> The Generic Pharmaceutical Association says it supports the FDA's plan to create quality metrics for companies and to do risk-based inspections but suggests the agency needs to phase them in to avoid drug shortages. Release

> Mundipharma is building a manufacturing plant in Singapore. Report

> Lannett has picked up a 300,000-square-foot manufacturing facility in Seymour, IN, as part of its $1.23 billion acquisition of Kremers Urban Pharmaceuticals, the specialty generic pharmaceuticals subsidiary of UCB. Release

> Packaging company Clariant will build a new plant in India to make pharma packaging. Report

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.